

James Paxton

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3607450/james-paxton-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

140
papers

3,985
citations

33
h-index

56
g-index

140
ext. papers

4,196
ext. citations

4.3
avg, IF

5.15
L-index

#	Paper	IF	Citations
140	Drug transfer and metabolism by the human placenta. <i>Clinical Pharmacokinetics</i> , 2004 , 43, 487-514	6.2	406
139	Interactions of herbs with cytochrome P450. <i>Drug Metabolism Reviews</i> , 2003 , 35, 35-98	7	320
138	Independent regulation of apical and basolateral drug transporter expression and function in placental trophoblasts by cytokines, steroids, and growth factors. <i>Drug Metabolism and Disposition</i> , 2007 , 35, 595-601	4	135
137	ABC drug transporter expression and functional activity in trophoblast-like cell lines and differentiating primary trophoblast. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2006 , 290, R1357-65	3.2	120
136	Improving the oral bioavailability of beneficial polyphenols through designed synergies. <i>Genes and Nutrition</i> , 2010 , 5, 75-87	4.3	118
135	UDP-glucuronosyltransferase activity, expression and cellular localization in human placenta at term. <i>Biochemical Pharmacology</i> , 2002 , 63, 409-19	6	91
134	Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery. <i>International Journal of Pharmaceutics</i> , 2009 , 367, 179-86	6.5	89
133	Metabolizing enzyme localization and activities in the first trimester human placenta: the effect of maternal and gestational age, smoking and alcohol consumption. <i>Human Reproduction</i> , 2002 , 17, 2564-72	5.7	88
132	The ABC transporter BCRP/ABCG2 is a placental survival factor, and its expression is reduced in idiopathic human fetal growth restriction. <i>FASEB Journal</i> , 2007 , 21, 3592-605	0.9	84
131	Identification of novel dietary phytochemicals inhibiting the efflux transporter breast cancer resistance protein (BCRP/ABCG2). <i>Food Chemistry</i> , 2013 , 138, 2267-74	8.5	74
130	Effects of carbamazepine on psychomotor performance in children as a function of drug concentration, seizure type, and time of medication. <i>Epilepsia</i> , 1990 , 31, 51-60	6.4	73
129	Active transport across the human placenta: impact on drug efficacy and toxicity. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2006 , 2, 51-69	5.5	65
128	Effect of sodium valproate on psychomotor performance in children as a function of dose, fluctuations in concentration, and diagnosis. <i>Epilepsia</i> , 1987 , 28, 115-24	6.4	63
127	Pharmacokinetics and pharmacodynamics of chlorambucil delivered in parenteral emulsion. <i>International Journal of Pharmaceutics</i> , 2008 , 360, 115-21	6.5	56
126	A highly sensitive fluorescent microplate method for the determination of UDP-glucuronosyl transferase activity in tissues and placental cell lines. <i>Drug Metabolism and Disposition</i> , 2000 , 28, 1184-6	4	55
125	Alpha 1-acid glycoprotein concentrations and propranolol binding in elderly patients with acute illness. <i>British Journal of Clinical Pharmacology</i> , 1984 , 18, 806-10	3.8	46
124	Enhanced pH-Responsiveness, Cellular Trafficking, Cytotoxicity and Long-circulation of PEGylated Liposomes with Post-insertion Technique Using Gemcitabine as a Model Drug. <i>Pharmaceutical Research</i> , 2015 , 32, 2428-38	4.5	44

123	Protein binding of methotrexate in sera from normal human beings: effect of drug concentration, pH, temperature, and storage. <i>Journal of Pharmacological Methods</i> , 1981 , 5, 203-13		44
122	Alpha 1 -acid glycoprotein and binding of basic drugs. <i>Methods and Findings in Experimental and Clinical Pharmacology</i> , 1983 , 5, 635-48		44
121	Expression, localisation and activity of ATP binding cassette (ABC) family of drug transporters in human amnion membranes. <i>Placenta</i> , 2007 , 28, 868-77	3.4	43
120	Pharmacokinetic and toxicity scaling of the antitumor agents amsacrine and CI-921, a new analogue, in mice, rats, rabbits, dogs, and humans. <i>Cancer Research</i> , 1990 , 50, 2692-7	10.1	42
119	Identification of the human liver cytochrome P450 isoenzyme responsible for the 6-methylhydroxylation of the novel anticancer drug 5,6-dimethylxanthenone-4-acetic acid. <i>Drug Metabolism and Disposition</i> , 2000 , 28, 1449-56	4	42
118	Modulatory effects of curcumin on multi-drug resistance-associated protein 5 in pancreatic cancer cells. <i>Cancer Chemotherapy and Pharmacology</i> , 2011 , 68, 603-10	3.5	41
117	Plasma disposition, metabolism and excretion of the experimental antitumour agent 5,6-dimethylxanthenone-4-acetic acid in the mouse, rat and rabbit. <i>Cancer Chemotherapy and Pharmacology</i> , 1999 , 43, 323-30	3.5	40
116	Inter-species variation in the metabolism and inhibition of N-[(2Fdimethylamino)ethyl]acridine-4-carboxamide (DACA) by aldehyde oxidase. <i>Biochemical Pharmacology</i> , 2000 , 59, 161-5	6	39
115	Interactions of dietary phytochemicals with ABC transporters: possible implications for drug disposition and multidrug resistance in cancer. <i>Drug Metabolism Reviews</i> , 2010 , 42, 590-611	7	38
114	Pharmacokinetics and pharmacodynamics of chlorambucil delivered in long-circulating nanoemulsion. <i>Journal of Drug Targeting</i> , 2010 , 18, 125-33	5.4	38
113	The xenobiotic transporter ABCG2 plays a novel role in differentiation of trophoblast-like BeWo cells. <i>Placenta</i> , 2007 , 28 Suppl A, S116-20	3.4	37
112	Effects of aspirin on salivary and serum phenytoin kinetics in healthy subjects. <i>Clinical Pharmacology and Therapeutics</i> , 1980 , 27, 170-8	6.1	36
111	Dietary polyacetyles of the faltarinol type are inhibitors of breast cancer resistance protein (BCRP/ABCG2). <i>European Journal of Pharmacology</i> , 2014 , 723, 346-52	5.3	34
110	5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy. <i>Investigational New Drugs</i> , 2002 , 20, 281-95	4.3	34
109	Concentrations and kinetics of carbamazepine in whole saliva, parotid saliva, serum ultrafiltrate, and serum. <i>Clinical Pharmacology and Therapeutics</i> , 1980 , 28, 695-702	6.1	34
108	The effects of dietary and herbal phytochemicals on drug transporters. <i>Advanced Drug Delivery Reviews</i> , 2017 , 116, 45-62	18.5	33
107	Blood-brain barrier penetration of felbamate. <i>Epilepsia</i> , 1992 , 33, 944-54	6.4	33
106	The effects of flavonoids on the ABC transporters: consequences for the pharmacokinetics of substrate drugs. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013 , 9, 267-85	5.5	32

105	The role of ABC and SLC transporters in the pharmacokinetics of dietary and herbal phytochemicals and their interactions with xenobiotics. <i>Current Drug Metabolism</i> , 2012 , 13, 624-39	3.5	32
104	3Fazido-3Tdeoxythymidine (AZT) induces apoptosis and alters metabolic enzyme activity in human placenta. <i>Toxicology and Applied Pharmacology</i> , 2003 , 192, 164-73	4.6	32
103	Production and characterisation of antisera to diphenylhydantoin suitable for radioimmunoassay. <i>Journal of Immunological Methods</i> , 1976 , 10, 317-27	2.5	32
102	Development of high-content gemcitabine PEGylated liposomes and their cytotoxicity on drug-resistant pancreatic tumour cells. <i>Pharmaceutical Research</i> , 2014 , 31, 2583-92	4.5	31
101	Human placental glucuronidation and transport of 3Fazido-3Tdeoxythymidine and uridine diphosphate glucuronic acid. <i>Drug Metabolism and Disposition</i> , 2004 , 32, 813-20	4	30
100	Identification and reactivity of the major metabolite (beta-1-glucuronide) of the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in humans. <i>Xenobiotica</i> , 2001 , 31, 277-93	2	30
99	Modulation of the pharmacokinetics of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice by thalidomide. <i>Cancer Chemotherapy and Pharmacology</i> , 2000 , 46, 135-41	3.5	29
98	Transport of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid and its acyl glucuronide by human intestinal Caco-2 cells. <i>European Journal of Pharmaceutical Sciences</i> , 2005 , 24, 513-24	5.1	28
97	Comparison of the blood-brain barrier and liver penetration of acridine antitumor drugs. <i>Cancer Chemotherapy and Pharmacology</i> , 1992 , 29, 439-44	3.5	28
96	Phenytoin concentrations in mixed, parotid and submandibular saliva and serum measured by radioimmunoassay. <i>British Journal of Clinical Pharmacology</i> , 1977 , 4, 185-91	3.8	28
95	Heterocyclic cyclohexanone monocarbonyl analogs of curcumin can inhibit the activity of ATP-binding cassette transporters in cancer multidrug resistance. <i>Biochemical Pharmacology</i> , 2015 , 93, 305-17	6	27
94	Effects of phenytoin on cognitive-motor performance in children as a function of drug concentration, seizure type, and time of medication. <i>Epilepsia</i> , 1994 , 35, 172-80	6.4	27
93	Cytosol mediated metabolism of the experimental antitumor agent acridine carboxamide to the 9-acridone derivative. <i>Biochemical Pharmacology</i> , 1991 , 42, 1879-84	6	27
92	Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles. <i>PLoS ONE</i> , 2015 , 10, e0130727	3.7	26
91	Predicting pharmacokinetic herb-drug interactions. <i>Drug Metabolism and Drug Interactions</i> , 2004 , 20, 143-58		26
90	Metabolism of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in cancer patients undergoing a phase I clinical trial. <i>Cancer Chemotherapy and Pharmacology</i> , 1999 , 44, 51-8	3.5	26
89	Hop-derived prenylflavonoids are substrates and inhibitors of the efflux transporter breast cancer resistance protein (BCRP/ABCG2). <i>Molecular Nutrition and Food Research</i> , 2014 , 58, 2099-110	5.9	25
88	A rapid, sensitive and specific radioimmunoassay for methotrexate. <i>Clinica Chimica Acta</i> , 1977 , 80, 563-70.2		25

87	Pharmacokinetics and toxicity of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide after i.v. administration in the mouse. <i>Cancer Chemotherapy and Pharmacology</i> , 1992 , 29, 379-84	3.5	24
86	The binding of amsacrine to human plasma proteins. <i>Journal of Pharmacy and Pharmacology</i> , 1986 , 38, 432-8	4.8	22
85	Species differences in the metabolism of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in vitro: implications for prediction of metabolic interactions in vivo. <i>Xenobiotica</i> , 2002 , 32, 87-107	2	21
84	Phase I trial of the amsacrine analogue 9-[(2-methoxy-4-[(methylsulfonyl)amino]phenyl)amino]-N,5-dimethyl-4-acridinecarboxamide (CI-921). <i>Cancer Research</i> , 1988 , 48, 6593-6	10.1	21
83	Development of Long-Circulating pH-Sensitive Liposomes to Circumvent Gemcitabine Resistance in Pancreatic Cancer Cells. <i>Pharmaceutical Research</i> , 2016 , 33, 1628-37	4.5	21
82	Plasma pharmacokinetics of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in a phase I trial. <i>Cancer Chemotherapy and Pharmacology</i> , 1999 , 44, 45-50	3.5	20
81	High-performance liquid-chromatographic method for the determination of 4F(9-acridinylamino)methanesulfon-m-anisidide in plasma. <i>Biomedical Applications</i> , 1983 , 276, 367-74		20
80	Propranolol binding in serum: comparison of methods and investigation of effects of drug concentration, pH, and temperature. <i>Journal of Pharmacological Methods</i> , 1983 , 10, 1-11		20
79	Salivary phenytoin radioimmunoassay. A simple method of the assessment of non-protein bound drug concentrations. <i>European Journal of Clinical Pharmacology</i> , 1977 , 11, 71-4	2.8	20
78	Development of a gradient high performance liquid chromatography assay for simultaneous analysis of hydrophilic gemcitabine and lipophilic curcumin using a central composite design and its application in liposome development. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014 , 98, 371-8	3.5	19
77	Determination of thalidomide in transport buffer for Caco-2 cell monolayers by high-performance liquid chromatography with ultraviolet detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2003 , 785, 165-73	3.2	19
76	Interaction of probenecid with the protein binding of methotrexate. <i>Pharmacology</i> , 1984 , 28, 86-9	2.3	19
75	Reversible binding of the novel anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid to plasma proteins and its distribution into blood cells in various species. <i>Journal of Pharmacy and Pharmacology</i> , 2001 , 53, 463-71	4.8	18
74	Pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (AS1404), a novel vascular disrupting agent, in phase I clinical trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2007 , 59, 681-7	3.5	18
73	Potentiation of the antitumour effect of cyclophosphamide in mice by thalidomide. <i>Cancer Chemotherapy and Pharmacology</i> , 2002 , 50, 186-92	3.5	18
72	In vitro and in vivo kinetic interactions of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid with thalidomide and diclofenac. <i>Cancer Chemotherapy and Pharmacology</i> , 2001 , 47, 319-26	3.5	18
71	Disposition of amsacrine and its analogue 9-[(2-methoxy-4-[(methylsulfonyl)amino]phenyl)amino]-N,5-dimethyl-4-acridinecarboxamide (CI-921) in plasma, liver, and Lewis lung tumors in mice. <i>Cancer Research</i> , 1990 , 50, 503-8	10.1	18
70	Prediction of herb-drug metabolic interactions: a simulation study. <i>Phytotherapy Research</i> , 2005 , 19, 464-71	6.7	17

69	Predicting pharmacokinetics and drug interactions in patients from in vitro and in vivo models: the experience with 5,6-dimethylxanthenone-4-acetic acid (DMXAA), an anti-cancer drug eliminated mainly by conjugation. <i>Drug Metabolism Reviews</i> , 2002 , 34, 751-90	7	17
68	The allometric approach for interspecies scaling of pharmacokinetics and toxicity of anti-cancer drugs. <i>Clinical and Experimental Pharmacology and Physiology</i> , 1995 , 22, 851-4	3	16
67	Pharmacokinetics of amsacrine in patients receiving combined chemotherapy for treatment of acute myelogenous leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 1985 , 14, 21-5	3.5	16
66	Thalidomide in cancer treatment: a potential role in the elderly?. <i>Drugs and Aging</i> , 2002 , 19, 85-100	4.7	15
65	Intraperitoneal administration of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in the mouse: bioavailability, pharmacokinetics and toxicity after a single dose. <i>Cancer Chemotherapy and Pharmacology</i> , 1992 , 31, 32-6	3.5	15
64	Bioavailability of metoprolol in young adults and the elderly, with additional studies on the effects of metoclopramide and probanthine. <i>European Journal of Clinical Pharmacology</i> , 1983 , 25, 353-6	2.8	15
63	Fluctuations in salivary carbamazepine and carbamazepine-10,11-epoxide concentrations during the day in epileptic children. <i>Epilepsia</i> , 1983 , 24, 716-24	6.4	15
62	Determination of two major metabolites of the novel anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid in hepatic microsomal incubations by high-performance liquid chromatography with fluorescence detection. <i>Biomedical Applications</i> , 1999 , 734, 129-36		14
61	Determination of N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino)phenylamino]-4-acridinecarboxamide in plasma by high-performance liquid chromatography. <i>Biomedical Applications</i> , 1985 , 342, 431-5		14
60	Transport of thalidomide by the human intestinal caco-2 monolayers. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2005 , 30, 49-61	2.7	13
59	Pharmacokinetics of acridine-4-carboxamide in the rat, with extrapolation to humans. <i>Cancer Chemotherapy and Pharmacology</i> , 1993 , 32, 323-5	3.5	13
58	The protein binding and elimination of methotrexate after intravenous infusions in cancer patients. <i>Clinical and Experimental Pharmacology and Physiology</i> , 1982 , 9, 225-34	3	13
57	Plasma protein binding of the experimental antitumour agent acridine-4-carboxamide in man, dog, rat and rabbit. <i>Journal of Pharmacy and Pharmacology</i> , 1994 , 46, 63-7	4.8	12
56	6-methylhydroxylation of the anti-cancer agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by flavin-containing monooxygenase 3. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2002 , 27, 179-83	2.7	12
55	Preclinical factors influencing the relative contributions of Phase I and II enzymes to the metabolism of the experimental anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid. <i>Biochemical Pharmacology</i> , 2003 , 65, 109-20	6	12
54	Effects of anticancer drugs on the metabolism of the anticancer drug 5,6-dimethylxanthenone-4-acetic (DMXAA) by human liver microsomes. <i>British Journal of Clinical Pharmacology</i> , 2001 , 52, 129-36	3.8	12
53	The evaluation of a radioimmunoassay for diphenylhydantoin using an iodinated tracer. <i>Clinica Chimica Acta</i> , 1977 , 79, 81-92	6.2	11
52	Enhancement of the action of the antivasular drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA; ASA404) by non-steroidal anti-inflammatory drugs. <i>Investigational New Drugs</i> , 2009 , 27, 280-4	4.3	10

51	Determination of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid and its acyl glucuronide in Caco-2 monolayers by liquid chromatography with fluorescence detection: application to transport studies. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2004 , 809, 87-97	3.2	10
50	Differences in the metabolism of the antitumour agents amsacrine and its derivative CI-921 in rat and mouse. <i>Xenobiotica</i> , 1992 , 22, 657-69	2	10
49	Comparison of the pharmacokinetics and protein binding of the anticancer drug, amsacrine and a new analogue, N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino)phenyl-amino]-4-acridinecarboxamide in rabbits. <i>Cancer Chemotherapy and Pharmacology</i> , 1986 , 16, 253-6	3.5	10
48	A difference between the rat and mouse in the pharmacokinetic interaction of 5,6-dimethylxanthenone-4-acetic acid with thalidomide. <i>Cancer Chemotherapy and Pharmacology</i> , 2001 , 47, 541-4	3.5	9
47	Blood-brain glucose transfer in the mouse. <i>Neurochemical Research</i> , 1993 , 18, 591-7	4.6	9
46	Involvement of glutathione in the metabolism of the anilinoacridine antitumour agents CI-921 and amsacrine. <i>Drug Metabolism and Drug Interactions</i> , 1988 , 6, 371-81		9
45	High-dose methotrexate therapy--an area of uncertainty. <i>Australian and New Zealand Journal of Medicine</i> , 1979 , 9, 722-32		9
44	Carbamazepine determination in saliva of children: enzyme immunoassay (EMIT) versus high pressure liquid chromatography. <i>Epilepsia</i> , 1982 , 23, 185-9	6.4	9
43	Comparison of a homologous series of benzonaphthyridine anti-cancer agents in mice: divergence between tumour and plasma pharmacokinetics. <i>Cancer Chemotherapy and Pharmacology</i> , 2012 , 70, 151-60	3.5	8
42	Pharmacokinetics and distribution of SN 28049, a novel DNA binding anticancer agent, in mice. <i>Cancer Chemotherapy and Pharmacology</i> , 2010 , 65, 1145-52	3.5	8
41	Gender differences in the metabolism and pharmacokinetics of the experimental anticancer agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). <i>Cancer Chemotherapy and Pharmacology</i> , 2002 , 49, 126-32	3.2	8
40	Determination of the covalent adducts of the novel anti-cancer agent 5,6-dimethylxanthenone-4-acetic acid in biological samples by high-performance liquid chromatography. <i>Biomedical Applications</i> , 2001 , 757, 343-8		8
39	The evaluation of a radioimmunoassay for phenothiazines and thioxanthenes using an iodinated tracer. <i>Journal of Immunological Methods</i> , 1979 , 31, 159-66	2.5	8
38	Conformational and chemical requirements for antibody recognition of diphenylhydantoin derivatives. <i>Immunochemistry</i> , 1976 , 13, 891-4		8
37	Curcumin and its cyclohexanone analogue inhibited human Equilibrative nucleoside transporter 1 (ENT1) in pancreatic cancer cells. <i>European Journal of Pharmacology</i> , 2017 , 803, 167-173	5.3	7
36	A rapid LC-MS/MS method for the quantitation of a series of benzonaphthyridine derivatives: application to in vivo pharmacokinetic and lipophilicity studies in drug development. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2012 , 63, 9-16	3.5	7
35	Development and validation of a liquid chromatography-mass spectrometry (LC-MS) assay for the determination of the anti-cancer agent N-[2-(dimethylamino)ethyl]-2,6-dimethyl-1-oxo-1,2-dihydrobenzo[b]-1,6-naphthyridine-4-carboxamide (SN 28049). <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2001 , 757, 343-8	3.2	7
34	Rat hepatocyte-mediated metabolism of the experimental anti-tumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide. <i>Xenobiotica</i> , 1993 , 23, 361-71	2	7

33	Tumour profile of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide after intraperitoneal administration in the mouse. <i>Cancer Chemotherapy and Pharmacology</i> , 1993 , 32, 320-2	3.5	7
32	Quantitation of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in plasma by high-performance liquid chromatography. <i>Biomedical Applications</i> , 1990 , 528, 385-94		7
31	Aberrantly high phenytoin concentrations in saliva. Precaution in monitoring phenytoin concentrations in whole saliva. <i>British Journal of Clinical Pharmacology</i> , 1979 , 8, 508-9	3.8	7
30	Selective cellular uptake and retention of SN 28049, a new DNA-binding topoisomerase II-directed antitumor agent. <i>Cancer Chemotherapy and Pharmacology</i> , 2014 , 74, 25-35	3.5	6
29	Use of whole saliva for bioavailability studies with reference to phenytoin. <i>Journal of Pharmacy and Pharmacology</i> , 1980 , 32, 586-8	4.8	6
28	Inhibition of human CYP1A2 oxidation of 5,6-dimethyl-xanthenone-4-acetic acid by acridines: a molecular modelling study. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2005 , 32, 633-9	3	6
27	Elimination kinetics of amsacrine in the rabbit: evidence of nonlinearity. <i>Pharmacology</i> , 1985 , 31, 50-6	2.3	6
26	Development and validation of bioanalytical method for the determination of asulacrine in plasma by liquid chromatography. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2008 , 46, 386-90	3.5	5
25	Preclinical factors affecting the interindividual variability in the clearance of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid. <i>Biochemical Pharmacology</i> , 2003 , 65, 1853-65	6	5
24	Co-Delivery Using pH-Sensitive Liposomes to Pancreatic Cancer Cells: the Effects of Curcumin on Cellular Concentration and Pharmacokinetics of Gemcitabine. <i>Pharmaceutical Research</i> , 2021 , 38, 1209-1219	4.5	5
23	Tumour tissue selectivity in the uptake and retention of SN 28049, a new topoisomerase II-directed anticancer agent. <i>Cancer Chemotherapy and Pharmacology</i> , 2013 , 72, 1013-22	3.5	4
22	The effect of food on the bioavailability and kinetics of the anticancer drug amsacrine and a new analogue, N-5-dimethyl-9-[(2-methoxy-4-methylsulphonylamino)phenylamino]-4-acridinecarboxamide in rabbits. <i>Journal of Pharmacy and Pharmacology</i> , 1986 , 38, 837-40	4.8	4
21	Determination of unbound concentration of the novel anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid in human plasma by ultrafiltration followed by high-performance liquid chromatography with fluorimetric detection. <i>Biomedical Applications</i> , 2001 , 757, 359-63		4
20	Thiolytic cleavage and binding of the antitumour agent CI-921 in blood. <i>Drug Metabolism and Drug Interactions</i> , 1988 , 6, 327-36		4
19	Enzyme immunoassay of carbamazepine in serum and saliva. <i>Journal of Pharmacological Methods</i> , 1980 , 3, 289-96		4
18	Interference of 4-amino-4-deoxy-N10-methylpteroic acid with the radioimmunoassay of methotrexate.. <i>Clinical Chemistry</i> , 1979 , 25, 491-492	5.5	4
17	Metabolism of the experimental antitumor agent acridine carboxamide in the mouse. <i>Drug Metabolism and Disposition</i> , 1993 , 21, 530-6	4	4
16	Dose-dependent pharmacokinetics of N-5-dimethyl-9-[(2-methoxy-4-methylsulphonylamino)phenylamino]- 4-acridinecarboxamide (CI-921) in rabbits. <i>Cancer Chemotherapy and Pharmacology</i> , 1987 , 20, 13-5	3.5	3

15	The clinical pharmacokinetics of N-5-dimethyl-9-[(2-methoxy-4-methyl-sulfonylamino)phenylamino]-4-acridinecarboxamide (CI-921) in a phase 1 trial. <i>Cancer Chemotherapy and Pharmacology</i> , 1988 , 22, 235-40	3.5	3
14	The effect of label affinity on the sensitivity and specificity of a hapten radioimmunoassay: a comparison of three [¹²⁵ I]diphenylhydantoin radioligands with the ¹⁴ C-labelled drug. <i>Journal of Immunological Methods</i> , 1979 , 27, 363-71	2.5	3
13	An indication of possible impending toxicity during moderately high dose methotrexate infusions. <i>British Journal of Clinical Pharmacology</i> , 1978 , 6, 551-2	3.8	3
12	Non-specific binding of the experimental anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in liver microsomes from various species. <i>Journal of Pharmacy and Pharmacology</i> , 2002 , 54, 997-1003	4.8	2
11	Strain differences in the liver microsomal metabolism of the experimental anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid in mice. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2002 , 776, 231-6	3.2	2
10	High-throughput screening of potential inhibitors for the metabolism of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2002 , 767, 19-26	3.2	2
9	The effect of cimetidine, phenobarbitone and buthionine sulphoximine on the disposition of N-5-dimethyl-9-[(2-methoxy-4-methyl-sulphonylamino)phenylamino]-4-acridinecarboxamide (CI-921) in the rabbit. <i>Cancer Chemotherapy and Pharmacology</i> , 1989 , 23, 291-5	3.5	2
8	Plasma and biliary disposition of pirenzepine in man. <i>Clinical and Experimental Pharmacology and Physiology</i> , 1986 , 13, 241-8	3	2
7	Absence of effect of propoxyphene on antipyrine kinetics in the rabbit. <i>Pharmacology</i> , 1983 , 27, 241-4	2.3	2
6	Farewell Peter Nigel Black FRACP. <i>Respirology</i> , 2010 , 15, 383-384	3.6	1
5	Maintenance of liver-specific function in cultured hepatocytes in different media. <i>Biochemical Society Transactions</i> , 1993 , 21, 70S	5.1	1
4	The effect of buthionine sulphoximine, cimetidine and phenobarbitone on the disposition of amsacrine in the rabbit. <i>Cancer Chemotherapy and Pharmacology</i> , 1986 , 18, 208-12	3.5	1
3	Sustained release of a corticosteroid using polymeric implants. <i>Agents and Actions</i> , 1986 , 19, 233-43		1
2	Radioimmunoassay of Methotrexate 1984 , 251-258		
1	Determination of the Anti-Cancer Drug Amsacrine in Biological Fluids by HPLC 1984 , 201-209		